Metastatic large cell neuroendocrine carcinoma of larynx: Individualizing tumor biology by dual tracer positron emission tomography/computed tomography (68Ga-DOTATATE and18F-fluorodeoxyglucose) molecular imaging and disease stabilization following177Lu-DOTATATE peptide receptor radionuclide therapy after initial progression on chemoradiotherapy
Debate exists on the disease biology and course of primary large cell neuroendocrine carcinoma (LCNEC) of larynx, being classified as a variant of atypical carcinoid by the World Health Organisation-2005 classification, while literature of its aggressive behavior indicating poorly differentiated neu...
Main Authors: | Sonali Jadhav, Sandip Basu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2019-01-01
|
Series: | World Journal of Nuclear Medicine |
Subjects: | |
Online Access: | http://www.wjnm.org/article.asp?issn=1450-1147;year=2019;volume=18;issue=4;spage=431;epage=433;aulast=Jadhav |
Similar Items
-
Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
by: Madhav Prasad Yadav, et al.
Published: (2019-02-01) -
Tissue dose estimation after extravasation of 177Lu-DOTATATE
by: Perrine Tylski, et al.
Published: (2021-03-01) -
Prevalence of hitherto unknown brain meningioma detected on 68Ga-DOTATATE positron-emission tomography/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of177Lu-DOTATATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors
by: Rahul V Parghane, et al.
Published: (2019-01-01) -
177Lu-DOTATATE peptide receptor radionuclide therapy in metastatic or advanced and inoperable primary neuroendocrine tumors of rare sites
by: Pradeep Thapa, et al.
Published: (2017-01-01) -
Evaluation of Kidney Dose in Neuroendocrine Tumors Patients after Peptide Receptor Radionuclide Therapy using 177Lu-DOTATATE
by: N.R. Hidayati, et al.
Published: (2019-12-01)